Lansoprazole 30 mg Orodispersible Tablets

Orodispersible tablet - white to yellowish white round, approximately 12.7 mm in diameter, flat-faced beveled edged tablet engraved with “LP2” on one side and “M” on other side with orange to dark brown speckles.

Therapeutic indications:
• Treatment of duodenal and gastric ulcer
• Treatment of reflux oesophagitis
• Prophylaxis of reflux oesophagitis
• Eradication of Helicobacter pylori (H. pylori) concurrently given with appropriate antibiotic therapy for treatment of H. pylori-associated ulcers
•Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment
• Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk (see section 4.2) requiring continued therapy
• Symptomatic gastro-oesophageal reflux disease.
• Zollinger-Ellison syndrome.

Features

Nature and contents of container:
The product is presented in the following pack types:
• Cold form perforated blister pack comprising of OPA-Aluminium-PVC on one side, and peelable plain peel paper-PET-Aluminium-HSL on the other side in cardboard cartons containing 7, 14, 28, 30, 56, 90 and 98 tablets.
• Perforated unit dose cold-form blisters comprising of OPA-Aluminium-PVC on one side, and peelable plain peel paper-PET-Aluminium-HSL on the other side in cardboard cartons containing 28 tablets.
• HDPE bottle pack comprising of HDPE bottle with absorbent cotton and polypropylene (PP) screw cap containing 30, 100 and 500 tablets.

The HDPE bottle pack may either be placed in an outer cardboard carton or provided without a carton based on market requirement.

Special precautions for storage:
• Store in the original package in order to protect from moisture.
• Once open keep bottle tightly closed.

Shelf life:
• Bottles: Use within 100 days of opening.